Navigation Links
Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
Date:2/3/2013

ZURICH, February 4, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) has been informed by Pfizer Inc. that the first patient has been dosed in a Phase 1 clinical trial with an anti-IgE vaccine, which is being developed under a license agreement between both parties. Pfizer's anti-IgE vaccine is based on Cytos' VLP ("virus-like-particle") vaccine platform.

Christian Itin , Chairman and Chief Executive Officer of Cytos, comments: "We are very pleased that Pfizer has advanced its anti-IgE vaccine to a Phase 1 clinical trial. This is an important milestone for the program and provides further evidence of the potential of Cytos' B-cell vaccine platform based on Qbeta-derived virus like particles."

Pfizer acquired world-wide exclusive rights to develop, manufacture and commercialize certain specified vaccines based on Cytos' VLP platform in 2009.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class biologic in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function and asthma control in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com

This foregoing press release may contain forward-looking statements that include words or phrases such as "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.


'/>"/>
SOURCE Cytos
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
2. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
3. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
4. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
5. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Aushon to Launch New Multiplex Immunoassay Platform
8. ZyDoc Selects Health Fidelitys REVEAL™ Natural Language Processing (NLP) Platform to Accelerate Time to Value for its MediSapien Web Services
9. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
10. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
11. WaferGen Bio-systems Launches MyDesign - Setting a New Standard in Flexibility with an Open Format High-Throughput qPCR Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... MELVILLE, N.Y. , Feb. 22, 2017 /PRNewswire/ ... has signed an exclusive distribution agreement with Rijuven, ... its CardioSleeve diagnostic device to medical practitioners. ... records synchronized electrocardiogram (ECG) and heart sound signals, ... via Bluetooth, and offers cloud-based analysis to help ...
(Date:2/22/2017)... HAYWARD, Calif. , Feb. 22, 2017  Applied Silver, ... Sue Barnes to the company,s advisory board. Ms. Barnes ... total, joining business, advertising, engineering, legal, and healthcare experts ... , John Goodrich , J. Tress Ritter , ... RN, BSN, CIC, FAPIC brings more than three decades of ...
(Date:2/22/2017)... DUBLIN , Feb. 22, 2017  Allergan ... is proud to be a Gold sponsor of ... National Educating America Tour." This tour commemorates AFA,s15 ... availability of services and programs. The tour will ... free memory screenings and displays of the AFA ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... PRP, the latest innovation in the delivery of Platelet Rich Plasma (PRP). PRP ... and pain management, to accelerate tissue synthesis and provide a faster and more ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of ... report that family members or friends have also commented about their poor hearing. ... wear hearing aids. One reason, suggested by 89 percent of American respondents, is ...
(Date:2/22/2017)... ... 2017 , ... Pet obesity in the U.S. continued to steadily increase in ... for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also found pet ... of corn and grains, value of raw and organic diets, and the best sources ...
(Date:2/22/2017)... Charleston, SC (PRWEB) , ... February 22, 2017 , ... ... one of several sponsors of the Medical University of South Carolina (MUSC) Center on ... in Mount Pleasant, SC. “MUSC’s Center on Aging is a tremendous resource in our ...
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased to announce ... Oven offers up to four ovens in one. Control temperature, fan speed and ... evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this game-changing ...
Breaking Medicine News(10 mins):